Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PHAT
STRONG SELLPhathom Pharmaceuticals, Inc. · Healthcare · United States · $912M · Avg Vol: $12M/d
COMPANY DESCRIPTION
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. Its lead product, Voquenza (vonoprazan), is a potassium-competitive acid blocker approved for certain acid-related disorders. The company's competitive position is driven by its differentiated therapeutic offerings and its strategic focus on the significant market for GI disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0.7M | 55.3M | 175.1M | 1502.4% | 204.9M | 333.8M | 90.6% |
| EPS | -5.05 | -3.93 | -5.29 | -3.03 | — | -2.09 | — | — |
| Shares | 41.5M | 58.0M | 68.5M | 71.4M | +72.2% | 79.8M | — | — |
| Debt | 97.1M | 139.0M | 201.9M | 211.8M | 29.7% | 547.2M | — | — |
| Equity | -74.8M | -72.8M | -253.6M | -438.2M | — | — | — | — |
| Op CF | -146.5M | -137.6M | -266.8M | -166.8M | — | -97.5M | — | — |
| Inv CF | -1.0M | -1.6M | -0.1M | -0.2M | — | — | — | — |
| Fin CF | 120.0M | 367.6M | 182.8M | -0.3M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PHAT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc.(you) | $912M | 19 | STRONG SELL |
| KURA | Kura Oncology, Inc. | $922M | 20 | STRONG SELL |
| ANNX | Annexon, Inc. | $855M | 16 | STRONG SELL |
| SVRA | Savara Inc. | $1.1B | 19 | STRONG SELL |
| JANX | Janux Therapeutics, Inc. | $935M | 23 | SELL |
| CAPR | Capricor Therapeutics, Inc. | $1.1B | 18 | STRONG SELL |
| AVTX | Avalo Therapeutics, Inc. | $976M | 23 | SELL |
| ACRS | Aclaris Therapeutics, Inc. | $730M | 20 | SELL |
| GERN | Geron Corporation | $911M | 26 | SELL |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $707M | 17 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%